Improving vaccine efficacy against malignant glioma

Erik Ladomersky, Matthew Genet, Lijie Zhai, Galina Gritsina, Kristen L. Lauing, Rishi R. Lulla, Jason Fangusaro, Alicia Lenzen, Priya Kumthekar, Jeffrey J. Raizer, David C. Binder, C. David James, Derek A. Wainwright*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

Original languageEnglish (US)
Article numbere1196311
Issue number8
StatePublished - Aug 2 2016


  • Cancer immunity
  • Dendritic cell vaccine
  • HSPPC-96
  • Immunosuppression
  • Rindopepimut
  • cancer vaccines
  • glioma
  • pediatric glioma

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Improving vaccine efficacy against malignant glioma'. Together they form a unique fingerprint.

Cite this